Plegridy Pen (peginterferon beta-1a) NDC 64406-011

NDC codes

FDA NDC Directory

Product NDC (as listed)64406-011Labeler and product segments. Claims need a package NDC.

Product NDC at billing width64406-0011Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
64406-011-01	64406001101	1 TRAY in 1 CARTON (64406-011-01) / 2 SYRINGE in 1 TRAY / .5 mL in 1 SYRINGE (64406-011-02)Marketed from Aug 15, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Plegridy PenSuffix: Pen
Generic name (nonproprietary): peginterferon beta-1a
Active ingredients: Peginterferon beta-1a — 125 ug/.5mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Biogen Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125499
Marketing start: Aug 15, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Interferon-beta (Chemical structure)
Identifiers: Product ID 64406-011_82966338-6ae8-490e-8f3a-f94f558fb43fSPL ID 82966338-6ae8-490e-8f3a-f94f558fb43fSPL set ID 08f0ea03-4e6d-195d-aef4-886e32befa95RxCUI 1546172, 1546177, 1546181, 1546183, 1546187, 1546189, 1546197, 1546198, 1649591, 1649593, 1649600, 1649601, 1649602, 1649603, 1649604, 1649605UNII I8309403R0
Pharmacologic class: Interferon beta

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N464406001101 followed by a unit qualifier and the quantity

Package 64406-0011-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 12, 2025.

Indications (excerpt from the label)

PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 125499

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 125499
Product	Strength	Form · route	Labeler	Product NDC
Plegridy Penpeginterferon beta-1a	—	KitSubcutaneous	Biogen Inc.	64406-012
Plegridypeginterferon beta-1a	Peginterferon beta-1a 125 ug/.5mL	Injection, SolutionSubcutaneous	Biogen Inc.	64406-015
Plegridypeginterferon beta-1a	—	KitSubcutaneous	Biogen Inc.	64406-016
Plegridypeginterferon beta-1a	Peginterferon beta-1a 125 ug/.5mL	Injection, SolutionIntramuscular	Biogen Inc.	64406-017